Date | Title | Description | Source |
30.04.2024 | Truvaga™ Plus Demonstrates Health Benefits in Latest Consume... | ROCKAWAY, N.J., April 30, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR),... | tullisfund... |
08.04.2024 | electroCore Announces the Launch of Truvaga Plus® for Genera... | ROCKAWAY, N.J., April 08, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-sta... | tullisfund... |
02.04.2024 | electroCore Expands Intellectual Property Portfolio | electroCore Granted Two New U.S. Patents
ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) — electroCo... | tullisfund... |
13.03.2024 | electroCore Announces Fourth Quarter and Full Year 2023 Fina... | Record full year 2023 net sales of $16.0 million increased 87% over $8.6 million for the full year 2... | tullisfund... |
13.03.2024 | electroCore Announces Fourth Quarter and Full Year 2023 Fina... | - | globenewsw... |
12.03.2024 | electroCore to Participate in Upcoming Investor Conferences | - | globenewsw... |
05.03.2024 | electroCore to Announce Fourth Quarter and Full Year Ended D... | - | globenewsw... |
06.02.2024 | electroCore Expands Intellectual Property Portfolio | ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stag... | tullisfund... |
09.01.2024 | electroCore Expands Intellectual Property Portfolio | ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stag... | tullisfund... |
26.12.2023 | electroCore Expands Intellectual Property Portfolio | electroCore Granted Two New U.S. Patents | tullisfund... |
17.10.2023 | electroCore Announces Two-Year Extension of gammaCore™ Devic... | Extension maintains listing through March 17, 2026 | tullisfund... |
10.10.2023 | Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS... | VANQUISH Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache As... | tullisfund... |
27.09.2023 | gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improv... | Two prospective, peer-reviewed trials demonstrate the symptomatic benefit of gammaCore in patients w... | tullisfund... |
26.09.2023 | electroCore Expands Intellectual Property Portfolio for Non-... | ROCKAWAY, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-sta... | tullisfund... |
31.07.2023 | electroCore, Inc. Announces $8.145 Million Registered Direct... | ROCKAWAY, N.J., July 31, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or ... | tullisfund... |
25.07.2023 | gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Impro... | ROCKAWAY, N.J., July 25, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stag... | tullisfund... |
18.07.2023 | electroCore Expands Intellectual Patent Portfolio for nVNS T... | ROCKAWAY, N.J., July 18, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stag... | tullisfund... |
13.07.2023 | electroCore, Inc. Announces Distribution Agreement with Reli... | ROCKAWAY, N.J., July 13, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stag... | tullisfund... |
11.07.2023 | electroCore Provides Select Second Quarter 2023 Financial Gu... | Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase ov... | tullisfund... |
06.07.2023 | gammaCore™ Selected for Study Funded by NFL and NFL Players ... | Research grants jointly awarded to independent medical researchers studying alternative pain managem... | tullisfund... |
27.06.2023 | electroCore’s TAC-STIM™ Non-Invasive Vagal Nerve Stimulation... | ROCKAWAY, N.J., June 27, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stag... | tullisfund... |
26.05.2023 | electroCore, Inc. Announces Departure of JP Errico from the ... | ROCKAWAY, N.J., May 26, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage... | tullisfund... |
26.04.2023 | National Institutes of Health Awards Grant for Pivotal Clini... | ROCKAWAY, N.J., April 26, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-sta... | tullisfund... |
24.04.2023 | Study Presented at 75th Annual Meeting of the American Acade... | Clinical trial (n=36) shows the ability of gammaCore (nVNS) to significantly improve the recall of a... | tullisfund... |
12.04.2023 | electroCore Expands Intellectual Patent Portfolio for nVNS T... | electroCore Granted Three New U.S. Patents | tullisfund... |
04.04.2023 | electroCore, Inc. Announces gammaCore Non-Invasive Vagus Ner... | ROCKAWAY, N.J., April 04, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR),... | tullisfund... |
17.01.2023 | electroCore Announces Expected Record 4Q 2022 Revenue of $2.... | ROCKAWAY, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a... | tullisfund... |
20.12.2022 | electroCore, Inc. Launches New Wellness Product Offering for... | Truvaga™ handheld non-invasive vagus nerve stimulator offers drug-free 2-minute sessions | tullisfund... |
07.07.2022 | electroCore, Inc. Announces Study of gammaCore Sapphire™ for... | Study to be initiated with Mayo Clinic’s Post-COVID Care Clinic subjects | tullisfund... |
24.05.2022 | electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Ne... | ROCKAWAY, N.J., May 24, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage... | tullisfund... |
18.01.2022 | electroCore Announces Shareholder Letter and Full-Year 2021 ... | Company anticipates full-year 2021 revenue of approximately $5.5 million, an approximately 55% incre... | tullisfund... |
12.01.2022 | gammaCore™ Non-Invasive Vagus Nerve Stimulation(nVNS) Receiv... | nVNS reduces symptoms of PTSD by 31% in sham-controlled study | tullisfund... |
11.01.2022 | electroCore, Inc. Broadens Patient Access to gammaCore with ... | E-Commerce platform allows patients to obtain prescriptions, purchase nVNS devices, and receive trai... | tullisfund... |
16.12.2021 | electroCore, Inc. Provides Update on Global Distribution Par... | ROCKAWAY, NJ, Dec. 16, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a ... | tullisfund... |
15.12.2021 | electroCore, Inc. Announces The Launch of a New Online Shop ... | ROCKAWAY, NJ, Dec. 15, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a ... | tullisfund... |
14.12.2021 | electroCore, Inc. Provides Update on nVNS to Treat Post Trau... | ROCKAWAY, NJ, Dec. 14, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a ... | tullisfund... |
13.12.2021 | electroCore Announces New Patent for Stroke and TIA Treatmen... | ROCKAWAY, NJ, Dec. 13, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a ... | tullisfund... |
04.11.2021 | electroCore Announces Third Quarter 2021 Financial Results | Third quarter 2021 revenue grew 17% sequentially and 38% over third quarter 2020 | tullisfund... |
29.09.2021 | electroCore Announces Open Access and Submission of Manuscri... | Study evaluated impact of non-invasive vagus nerve stimulation in hospitalized COVID-19 patients | tullisfund... |
15.09.2021 | electroCore Announces New Patent Expanding Claims Related to... | ECOR’s eighth US patent allows patients to self-treat medical conditions such as migraine headache u... | tullisfund... |
14.09.2021 | electroCore Announces 510(k) Clearance of gammaCore™ Non-Inv... | These rare forms of trigeminal autonomic cephalalgias are typically debilitating and difficult to tr... | tullisfund... |
24.08.2021 | electroCore Announces New Reseller Agreement with Red One Me... | Partnership will expand gammaCore federal market availability | tullisfund... |
05.08.2021 | electroCore Announces Second Quarter 2021 Financial Results | Second quarter 2021 net sales of $1.3 million, increased 69% over second quarter 2020 and 5% sequent... | tullisfund... |
27.07.2021 | electroCore Announces Issuance of New Patent for Migraine Tr... | Newly allowed patent is latest U.S. patent to issue in connection with electroCore’s non-invasive de... | tullisfund... |
30.06.2021 | electroCore Announces Pricing of $18.0 Million Public Offeri... | Company intends to use the net proceeds of the offering for sales and marketing, working capital, an... | tullisfund... |
24.06.2021 | electroCore Announces Publication of Study on the Effect of ... | Peer-reviewed paper available in the journal Communications Biology | tullisfund... |
23.06.2021 | electroCore, Inc. Announces Exclusive Distribution Agreement... | Three-year term for exclusive distribution of gammaCore Sapphire™ non-invasive nerve stimulator | tullisfund... |
16.06.2021 | electroCore to Join Russell Microcap® Index | Effective after the open of trading on June 28, 2021 | tullisfund... |
02.06.2021 | electroCore Announces Publication of Study on Non-Invasive V... | Peer-reviewed paper appears in the journal NPJ Parkinson’s Disease | tullisfund... |
06.05.2021 | electroCore Announces First Quarter 2021 Financial Results | Record first quarter 2021 net sales of $1.2 million, increased 64% over first quarter 2020 and 30% s... | tullisfund... |
26.04.2021 | electroCore, Inc. Announces Johns Hopkins University School ... | Economic impact of gastroparesis can be substantial, with studies reporting 11% of patients disabled... | tullisfund... |
20.04.2021 | electroCore, Inc. Announces Exclusive Distribution Agreement... | Introduction of nVNS therapy, gammaCore Sapphire, in the Middle East | tullisfund... |
15.04.2021 | electroCore Announces Publication in Nature Reviews: Neurolo... | gammaCore identified as the only therapy that shown to be effective in clinical trials for both acut... | tullisfund... |
13.04.2021 | electroCore Provides Business Update and Select First Quarte... | ROCKAWAY, NJ, April 13, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage... | tullisfund... |
08.04.2021 | electroCore Announces Top Line Results from SAVIOR-1 Study o... | nVNS Decreases Certain Biomarkers Associated with the Severity of COVID-19 through Five Days of Trea... | tullisfund... |
23.03.2021 | electroCore, Inc. Announces Exclusive Distribution Agreement... | Silvert Medical will serve as exclusive distributor of gammaCore Sapphire™ in Belgium, Luxembourg, t... | tullisfund... |
15.03.2021 | Chief Medical Officer of electroCore, Inc. Peter Staats, M.D... | ROCKAWAY, N.J.–(BUSINESS WIRE)–Mar. 15, 2021– Amid the vaccine rollout, 97,309 new cases of COVID-19... | tullisfund... |
11.03.2021 | electroCore Announces Fourth Quarter and Full Year 2020 Fina... | Full year 2020 net sales of approximately $3.5 million increased 46% over $2.4 million for full year... | tullisfund... |
24.02.2021 | Non-Invasive Vagus Nerve Stimulation (nVNS) Enters New Stage... | electroCore and the Hospital Clínico Universitario de Valencia have completed patient enrollment in ... | tullisfund... |
11.02.2021 | electroCore Announces Completion of Enrollment in SAVIOR-1 S... | Spain-based study has enrolled 110 patients over 18 years of age with respiratory failure secondary ... | tullisfund... |
12.11.2020 | electroCore Announces Third Quarter Financial Results | BASKING RIDGE, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial... | tullisfund... |
13.08.2020 | electroCore Announces Second Quarter Financial Results | Received EUA and initiated gammaCore Sapphire CV distribution process for certain known or suspected... | tullisfund... |
28.07.2020 | electroCore Announces Non-Invasive Vagus Nerve Stimulation C... | Paper supports use of nVNS as a front-line therapy for acute and preventative treatment of cluster h... | tullisfund... |
13.11.2019 | electroCore Announces Third Quarter 2019 Financial Results | Continued growth in prescribing physicians, paid months of therapy and dispensed prescriptions | tullisfund... |
30.09.2019 | electroCore Appoints Medical Technology Veteran Daniel S. Go... | 35-year biotechnology and medical technology veteran to lead bio-electric medicine company | tullisfund... |
25.09.2019 | electroCore Provides Update on 510(k) Submission Seeking Exp... | Additional information requested by FDA; Premium 2 trial progressing as planned | tullisfund... |
27.03.2019 | ElectroCore Announces Fourth Quarter and Full Year 2018 Fina... | Fourth quarter 2018 prescription growth of more than 30% from third quarter 2018 | tullisfund... |
08.03.2019 | ElectroCore Appoints Multiple Industry Veterans to Key Manag... | Dr. Tony Florino to serve as Chief Medical Officer and Brian Posner as Chief Financial Officer | tullisfund... |
23.10.2018 | Nice Publishes Advice on GammaCore for the Treatment of Clus... | Report contributors agreed gammaCore was highly innovative, may be more effective than standard of c... | tullisfund... |
30.11.2017 | Term Sheet — Thursday, November 30 | A WILD WEDNESDAY
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see ... | fortune.co... |
29.11.2017 | electroCore Completes Over $70M Series B Financing | electroCore, a Basking Ridge, NJ-based bioelectronic medicine healthcare company,, completed an over... | finsmes.co... |